STOCK TITAN

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
IDEAYA Biosciences (NASDAQ: IDYA) has granted non-qualified stock options to nine newly hired employees as part of their employment inducement package. The Compensation Committee approved options to purchase 664,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. The options were priced at $20.05 per share, matching IDEAYA's closing price on the Nasdaq Global Select Market on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) ha concesso opzioni su azioni non qualificate a nove nuovi dipendenti come parte del pacchetto di incentivazione all'assunzione. Il Comitato per la Remunerazione ha approvato opzioni per l'acquisto di 664.600 azioni ordinarie nell'ambito del Piano di Incentivi per l'Assunzione 2023 della società. Le opzioni sono state valutate a 20,05 dollari per azione, pari al prezzo di chiusura di IDEAYA sul Nasdaq Global Select Market alla data di assegnazione. Queste opzioni, della durata di 10 anni, matureranno in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei tre anni successivi, a condizione che il rapporto di lavoro continui.
IDEAYA Biosciences (NASDAQ: IDYA) ha otorgado opciones sobre acciones no calificadas a nueve empleados recién contratados como parte de su paquete de incentivos por empleo. El Comité de Compensación aprobó opciones para comprar 664,600 acciones comunes bajo el Plan de Incentivos para Contratación 2023 de la empresa. Las opciones se valoraron en 20,05 dólares por acción, igualando el precio de cierre de IDEAYA en el Nasdaq Global Select Market en la fecha de concesión. Estas opciones de 10 años se consolidarán en cuatro años, con un 25% consolidado tras el primer año y el 75% restante consolidado mensualmente durante los siguientes tres años, condicionado a la continuidad laboral.
IDEAYA Biosciences(NASDAQ: IDYA)는 고용 유인 패키지의 일환으로 새로 채용된 9명의 직원에게 비자격 스톡옵션을 부여했습니다. 보상 위원회는 회사의 2023년 고용 유인 인센티브 상 계획에 따라 664,600주의 보통주를 매수할 수 있는 옵션을 승인했습니다. 옵션 가격은 부여일 기준 나스닥 글로벌 셀렉트 마켓에서 IDEAYA의 종가인 주당 20.05달러와 동일합니다. 이 10년 만기 옵션은 4년에 걸쳐 베스팅되며, 첫 해 후 25%가 베스팅되고 나머지 75%는 이후 3년 동안 매월 베스팅되며, 계속 고용 상태인 경우에 한합니다.
IDEAYA Biosciences (NASDAQ : IDYA) a accordé des options d'achat d'actions non qualifiées à neuf nouveaux employés dans le cadre de leur package d'incitation à l'embauche. Le comité de rémunération a approuvé des options permettant d'acheter 664 600 actions ordinaires dans le cadre du Plan d'incitation à l'embauche 2023 de la société. Les options ont été fixées à 20,05 $ par action, correspondant au cours de clôture d'IDEAYA sur le Nasdaq Global Select Market à la date d'attribution. Ces options d'une durée de 10 ans seront acquises sur une période de quatre ans, avec 25 % acquis après la première année et les 75 % restants acquis mensuellement sur les trois années suivantes, sous réserve de la poursuite de l'emploi.
IDEAYA Biosciences (NASDAQ: IDYA) hat neun neu eingestellten Mitarbeitern im Rahmen ihres Einstellungsanreizpakets nicht qualifizierte Aktienoptionen gewährt. Der Vergütungsausschuss genehmigte Optionen zum Kauf von 664.600 Stammaktien gemäß dem Employment Inducement Incentive Award Plan 2023 des Unternehmens. Die Optionen wurden mit 20,05 USD pro Aktie bewertet, entsprechend dem Schlusskurs von IDEAYA am Nasdaq Global Select Market am Zuteilungsdatum. Diese 10-jährigen Optionen werden über vier Jahre erworben, wobei 25 % nach dem ersten Jahr und die restlichen 75 % monatlich über die folgenden drei Jahre vesten, vorausgesetzt, das Arbeitsverhältnis besteht weiterhin.
Positive
  • Attraction of new talent with equity compensation indicates company growth and expansion
  • Long-term vesting schedule of 4 years helps retain key employees
Negative
  • Potential dilution of existing shareholders from the issuance of 664,600 new stock options

SOUTH SAN FRANCISCO, Calif., May 30, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 29, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 664,600 shares of the Company's common stock to nine newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $20.05 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer 
investor@ideayabio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302468986.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

How many stock options did IDEAYA Biosciences (IDYA) grant to new employees in May 2025?

IDEAYA Biosciences granted stock options to purchase 664,600 shares of common stock to nine newly hired employees.

What is the exercise price for IDYA's May 2025 inducement stock options?

The stock options have an exercise price of $20.05 per share, equal to IDEAYA's closing price on the grant date.

What is the vesting schedule for IDEAYA's May 2025 inducement stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years.

What is the purpose of IDEAYA Biosciences' 2023 Inducement Plan?

The 2023 Inducement Plan is exclusively used to grant equity awards to new employees as an inducement for joining IDEAYA, in accordance with Nasdaq Rule 5635(c)(4).
Ideaya Biosciences

NASDAQ:IDYA

IDYA Rankings

IDYA Latest News

IDYA Stock Data

1.64B
86.79M
1.04%
109.56%
10.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO